1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Psychedelics Pipeline Overview: R&D Blossoms But No Panacea Among Candidates

 
• By Ayisha Sharma

While the psychedelic approach to mental health has recently achieved some clinical and regulatory validation, executives in the space warn the drugs cannot cure all and barriers to market remain.  

One of the compounds in the pipeline, psilocybin, is found in liberty cap mushrooms • Source: Shutterstock

Following a staggered development history set back by the "war on drugs", biotech firms have in recent years kick-started R&D into psychedelics, but despite a blooming clinical pipeline, the field has several challenges to overcome ranging from the risk-averse attitude of potential big pharma partners to identifying the right patients for treatment.

Psychedelics, also known as ‘classical hallucinogens’, are compounds which share a chemical structure similar to the neurotransmitter serotonin, and include...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

ASCO: Carvykti Data Raise Possibility Of Myeloma Cure

 
• By Alaric DeArment

J&J presented data at the American Society of Clinical Oncology meeting showing more than five-year disease- and therapy-free survival, but a myeloma working group will need to define what makes a cure.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.